BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17498528)

  • 1. Breast cancer risk assessment and risk reduction.
    Newman LA; Vogel VG
    Surg Clin North Am; 2007 Apr; 87(2):307-16, vii-viii. PubMed ID: 17498528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of breast cancer for women at high risk.
    Chan K; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
    Layeequr Rahman R; Crawford S
    Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
    Vogel VG
    J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
    Crowell EB; Jubelirer SJ
    W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of breast cancer (Part II): risk reduction strategies.
    Tirona MT; Sehgal R; Ballester O
    Cancer Invest; 2010 Dec; 28(10):1070-7. PubMed ID: 20932221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription of tamoxifen for breast cancer prevention by primary care physicians.
    Armstrong K; Quistberg DA; Micco E; Domchek S; Guerra C
    Arch Intern Med; 2006 Nov; 166(20):2260-5. PubMed ID: 17101945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of breast cancer chemoprevention.
    Chang JC
    Biomed Pharmacother; 1998; 52(3):133-6. PubMed ID: 9755806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status of breast cancer chemoprevention: a star is born.
    Morrow M; Jordan VC
    J Surg Oncol; 2007 Jan; 95(1):4-5. PubMed ID: 17192883
    [No Abstract]   [Full Text] [Related]  

  • 14. Women at high risk for breast cancer: preventive strategies.
    Sakorafas GH
    Mt Sinai J Med; 2002 Sep; 69(4):264-6. PubMed ID: 12357269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DM effort seeks to improve outcomes through prevention, early detection of breast cancer.
    Dis Manag Advis; 2000 Sep; 6(9):140-4, 132. PubMed ID: 11125466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen (TAM): the dispute goes on.
    Grilli S
    Ann Ist Super Sanita; 2006; 42(2):170-3. PubMed ID: 17033137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer risk in primary care: implications for chemoprevention.
    Lewis CL; Kinsinger LS; Harris RP; Schwartz RJ
    Arch Intern Med; 2004 Sep; 164(17):1897-903. PubMed ID: 15451765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.